$CAPR
CAPRICOR THERAPEUTICS, INC.

2022 Q3 Form 10-Q Financial Statement

#000155837022013383 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $1.592M $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.565M $2.357M $2.716M
YoY Change 42.45% 31.66% 42.19%
% of Gross Profit
Research & Development $5.500M $5.000M $5.100M
YoY Change 120.0% 42.86% 54.55%
% of Gross Profit
Depreciation & Amortization $137.0K $112.0K $92.49K
YoY Change 111.73% 114.05% 84.47%
% of Gross Profit
Operating Expenses $8.069M $7.322M $7.832M
YoY Change 87.03% 38.48% 50.55%
Operating Profit -$6.478M -$7.322M -$7.832M
YoY Change 50.14% 44.04% 51.74%
Interest Expense $106.6K $21.76K $13.44K
YoY Change 584.91% 29.99% 34.4%
% of Operating Profit
Other Income/Expense, Net $106.6K $212.3K $13.44K
YoY Change -72.14% -36.6% 46.64%
Pretax Income -$6.371M -$7.109M -$7.818M
YoY Change 62.04% 49.73% 51.81%
Income Tax
% Of Pretax Income
Net Earnings -$6.371M -$7.109M -$7.818M
YoY Change 62.04% 49.73% 51.75%
Net Earnings / Revenue -400.3%
Basic Earnings Per Share -$0.26 -$0.29 -$0.32
Diluted Earnings Per Share -$0.26 -$0.29 -$0.32
COMMON SHARES
Basic Shares Outstanding 24.35M 24.32M 24.28M
Diluted Shares Outstanding 24.43M 24.32M 24.28M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.61M $51.42M $58.33M
YoY Change 14.14% 35.03% 39.29%
Cash & Equivalents $8.414M $16.39M $58.30M
Short-Term Investments $38.20M $35.02M
Other Short-Term Assets $343.7K $659.3K $943.3K
YoY Change 23.22% 0.91% 27.47%
Inventory
Prepaid Expenses
Receivables $547.6K $547.6K $357.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $47.50M $52.62M $59.63M
YoY Change 15.03% 35.87% 39.92%
LONG-TERM ASSETS
Property, Plant & Equipment $3.591M $2.629M $2.329M
YoY Change 137.28% 136.85% 177.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $268.2K $268.2K $275.7K
YoY Change -7.11% 202.33% 206.36%
Total Long-Term Assets $6.423M $5.442M $5.288M
YoY Change 256.4% 353.95% 474.75%
TOTAL ASSETS
Total Short-Term Assets $47.50M $52.62M $59.63M
Total Long-Term Assets $6.423M $5.442M $5.288M
Total Assets $53.93M $58.07M $64.92M
YoY Change 25.12% 45.42% 49.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.937M $3.222M $4.098M
YoY Change 31.73% 1.52% 18.11%
Accrued Expenses $697.6K $579.7K $498.4K
YoY Change
Deferred Revenue $18.60M $15.70M $9.700M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.19M $19.55M $14.32M
YoY Change 676.18% 515.92% 281.95%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.376M $3.376M
YoY Change 0.0% 0.0% -0.99%
Other Long-Term Liabilities $11.93M $16.41M $22.58M
YoY Change
Total Long-Term Liabilities $15.31M $19.79M $25.96M
YoY Change 353.37% 486.13% 661.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.19M $19.55M $14.32M
Total Long-Term Liabilities $15.31M $19.79M $25.96M
Total Liabilities $38.50M $39.34M $40.28M
YoY Change 504.94% 500.57% 462.56%
SHAREHOLDERS EQUITY
Retained Earnings -$129.4M -$123.0M -$115.9M
YoY Change 26.98% 25.58%
Common Stock $144.7M $141.7M $140.5M
YoY Change 4.37% 7.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.43M $18.73M $24.64M
YoY Change
Total Liabilities & Shareholders Equity $53.93M $58.07M $64.92M
YoY Change 25.12% 45.42% 49.11%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.371M -$7.109M -$7.818M
YoY Change 62.04% 49.73% 51.75%
Depreciation, Depletion And Amortization $137.0K $112.0K $92.49K
YoY Change 111.73% 114.05% 84.47%
Cash From Operating Activities -$5.686M -$6.542M $24.05M
YoY Change 70.33% 44.94% -822.26%
INVESTING ACTIVITIES
Capital Expenditures -$1.099M -$412.6K $567.6K
YoY Change 134.77% 29.18% 1437.75%
Acquisitions
YoY Change
Other Investing Activities -$3.077M -$35.00M
YoY Change
Cash From Investing Activities -$4.177M -$35.41M -$625.4K
YoY Change 791.97% 10988.27% 1594.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.882M 15.00K 27.47K
YoY Change -71.35% -98.55% -99.78%
NET CHANGE
Cash From Operating Activities -5.686M -6.542M 24.05M
Cash From Investing Activities -4.177M -35.41M -625.4K
Cash From Financing Activities 1.882M 15.00K 27.47K
Net Change In Cash -7.980M -41.94M 23.45M
YoY Change -389.02% 1004.29% 154.5%
FREE CASH FLOW
Cash From Operating Activities -$5.686M -$6.542M $24.05M
Capital Expenditures -$1.099M -$412.6K $567.6K
Free Cash Flow -$4.586M -$6.130M $23.48M
YoY Change 59.82% 46.14% -797.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24324156
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22861051
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24303564
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22546634
dei Entity Central Index Key
EntityCentralIndexKey
0001133869
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24334952
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24185001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24334952
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34058
dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150, San Diego
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
358-3200
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
dei Trading Symbol
TradingSymbol
CAPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24346233
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16394067
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34885274
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
35022883
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
391750
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
659269
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1159937
CY2022Q2 us-gaap Assets Current
AssetsCurrent
52623799
CY2021Q4 us-gaap Assets Current
AssetsCurrent
36436961
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2629114
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1795696
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2544489
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2821944
CY2022Q2 us-gaap Other Assets
OtherAssets
268172
CY2021Q4 us-gaap Other Assets
OtherAssets
275722
CY2022Q2 us-gaap Assets
Assets
58065574
CY2021Q4 us-gaap Assets
Assets
41330323
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3127836
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3116371
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
94135
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
599388
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
579672
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
417632
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15745576
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19547219
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4133391
CY2022Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2158677
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2452707
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14254424
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
19789360
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5828966
CY2022Q2 us-gaap Liabilities
Liabilities
39336579
CY2021Q4 us-gaap Liabilities
Liabilities
9962357
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24185001
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
24335
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
24185
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
141669614
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
139404060
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22830
us-gaap Net Income Loss
NetIncomeLoss
-14927505
us-gaap Net Income Loss
NetIncomeLoss
-9900189
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22830
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22830
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24334952
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122987784
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108060279
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18728995
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58065574
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41330323
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
204082
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
244898
CY2021Q2 us-gaap Revenues
Revenues
204082
us-gaap Revenues
Revenues
244898
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4965088
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3497275
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10080787
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6793597
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2356666
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1789974
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5072501
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3695556
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
7321754
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5287249
us-gaap Operating Expenses
OperatingExpenses
15153288
us-gaap Operating Expenses
OperatingExpenses
10489153
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7321754
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5083167
us-gaap Operating Income Loss
OperatingIncomeLoss
-15153288
us-gaap Operating Income Loss
OperatingIncomeLoss
-10244255
CY2022Q2 us-gaap Other Income
OtherIncome
190582
us-gaap Other Income
OtherIncome
190582
CY2022Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
21761
CY2021Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
16741
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
35201
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
25906
CY2021Q2 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
318160
capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
318160
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
212343
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
334901
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
225783
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
344066
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7109411
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4748266
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7086581
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4748266
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14904675
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9900189
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24324156
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22861051
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24303564
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22546634
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1065329
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27465
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7818094
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
24642666
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1157904
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15006
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22830
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7109411
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18728995
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28199784
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12578526
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
752962
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1436
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5151923
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
36380785
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1035312
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
712299
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4748266
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
33380130
us-gaap Profit Loss
ProfitLoss
-14927505
us-gaap Profit Loss
ProfitLoss
-9900189
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
204501
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
102332
us-gaap Share Based Compensation
ShareBasedCompensation
2223233
us-gaap Share Based Compensation
ShareBasedCompensation
1465261
capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
318160
capr Noncash Lease Expenses
NoncashLeaseExpenses
145466
capr Noncash Lease Expenses
NoncashLeaseExpenses
0
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
155830
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-500668
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-357873
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-7550
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
11465
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
82391
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-505253
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
366679
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30000000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
748575
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
359371
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
17504295
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7843813
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
49012053
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14012000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
289345
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36037973
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-359371
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13613838
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
42471
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1436
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42471
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13615274
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18491207
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5412090
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32665874
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16394067
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38077964
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</p>
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
51400000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34900000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30000000.0
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2022Q2 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
547580
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the assumptions used to estimate stock-based </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
us-gaap Depreciation
Depreciation
204501
us-gaap Depreciation
Depreciation
100167
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.04
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.82
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3571690
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2552408
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
942576
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
756712
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2629114
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1795696
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000000.0
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10100000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.27
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7100000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4700000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14900000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6142203
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3748962
capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
318160
capr Commission Rate On Sale Price Per Share
CommissionRateOnSalePricePerShare
0.030
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24334952
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2021Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q2 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
269731
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
710142
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2500000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
823084
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3500000
CY2021Q2 capr Sharebased Compensation Arrangement By Sharebased Payment Award Percentage Of Annual Increase In Number Of Shares Authorized
SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized
0.05
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1209250
CY2022Q2 capr Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant
2601223
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.029
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.005
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1157904
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
712299
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2223233
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1465261
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2022Q2 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
51100000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
321677
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
656678
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
674931
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
693732
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
562627
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2909645
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
171296
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2738349
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
579672
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2158677
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2738349
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M14D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0275
capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2022Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30000000.0
CY2022Q1 capr Potential Milestone Payments
PotentialMilestonePayments
705000000.0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30000000.0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30000000.0
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15700000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14300000
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
94135
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
599388
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1700000
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
245000

Files In Submission

Name View Source Status
0001558370-22-013383-index-headers.html Edgar Link pending
0001558370-22-013383-index.html Edgar Link pending
0001558370-22-013383.txt Edgar Link pending
0001558370-22-013383-xbrl.zip Edgar Link pending
capr-20220630.xsd Edgar Link pending
capr-20220630x10q.htm Edgar Link pending
capr-20220630xex31d1.htm Edgar Link pending
capr-20220630xex31d2.htm Edgar Link pending
capr-20220630xex32d1.htm Edgar Link pending
capr-20220630xex32d2.htm Edgar Link pending
capr-20220630_cal.xml Edgar Link unprocessable
capr-20220630x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
capr-20220630_pre.xml Edgar Link unprocessable
capr-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20220630_lab.xml Edgar Link unprocessable